Today, Amylyx announced that their Phase 3 PHOENIX trial, a global, 48-week, randomized, placebo-controlled study of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine; also known as ALBRIOZA) in people living with ALS, did not meet its prespecified primary or secondary endpoints.

It’s understandable if this outcome has left us all feeling disheartened and discouraged. Now, more than ever, we must continue to stand united, support each other and continue to foster an environment of resilience and determination. Despite the setbacks we may face, let us not lose sight of the progress we have made and the potential for even greater achievements in the future.

➡ If you are currently taking Albrioza as a treatment, please reach out to your neurologists to discuss your options.

👉 Click here to read Amylyx Pharmaceuticals’ press release :

Let’s continue to embody hope together. 💙✨

Share this article.